Cornerstone pharmaceuticals announces published data on cpi-613® (devimistat) as an effective approach to targeting carcinoma catabolism

Cranbury, n.j., june 16, 2022 (globe newswire) -- cornerstone pharmaceuticals, inc. (“cornerstone” or the “company”), a company focused on rare cancer therapeutics and formerly known as rafael pharmaceuticals, today announced a publication on preclinical data supporting cpi-613® (devimistat) targeting carcinoma catabolism.
RFL Ratings Summary
RFL Quant Ranking